We are live on ! Find out more
NVCT icon

Nuvectis Pharma

31 hedge funds and large institutions have $7.15M invested in Nuvectis Pharma in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

181% more capital inflows, than outflows

Capital inflows: $2.63M | Capital outflows: $936K

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

1.21% more ownership

Funds ownership: 5.63% → 6.84% (+1.2%)

0% more funds holding

Funds holding: 31 → 31 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

Holders
31
Holders Change
–
Holders Change %
0%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
14
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NVCT Hedge Fund Activity: Q4 2024 in Review

31 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2024, worth a combined $7.15M — up 8.3% from $6.6M a quarter earlier.

Fund positioning in NVCT was balanced in Q4 2024: 7 funds opened new positions, 7 closed out, 14 added to existing stakes and 8 trimmed.

The largest buyer was Baldwin Wealth Partners, adding an estimated $1.14M. The largest seller was Iridian Asset Management, exiting entirely with an estimated $348K sold.

  • 31 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $7.15M of Nuvectis Pharma stock for Q4 2024, up 8.3% quarter-over-quarter.
  • 7 funds opened new Nuvectis Pharma positions in Q4 2024 and 7 closed out, a net change of 0 holders.
  • The largest Nuvectis Pharma buyer in Q4 2024 was Baldwin Wealth Partners, an estimated $1.14M added.
  • The largest Nuvectis Pharma seller in Q4 2024 was Iridian Asset Management, an estimated $348K sold.

Based on aggregated 13F filings for Q4 2024.